Gut Microbiota Signatures Associate with Chemotherapy-Related Adverse Events in Breast Cancer Patients

Area of Science:

• Oncology
• Microbiome Research
• Cancer Therapeutics

Background:

• Chemotherapy-induced adverse events negatively affect cancer treatment outcomes and patient quality of life.
• Gut microbiota composition is increasingly recognized for its role in individual susceptibility to chemotherapy toxicity.
• Understanding these links is crucial for improving patient care during cancer treatment.

Purpose of the Study:

• To investigate associations between gut microbiome alterations and specific chemotherapy-related adverse events.
• To identify potential microbiome-based biomarkers for predicting chemotherapy toxicity.
• To explore personalized cancer treatment strategies based on gut microbial signatures.

Main Methods:

• Prospective cohort study of 81 breast cancer patients undergoing chemotherapy.
• 16S rRNA sequencing for gut microbiome composition analysis.
• Statistical analyses including diversity metrics, LEfSe, and effect size calculations to identify significant associations.

Main Results:

• Significant associations found between 42 gut taxa and chemotherapy toxicities (FDR q < 0.05).
• Severe anemia linked to Eubacteriaceae and Eubacterium enrichment; severe neutropenia to depletion of butyrate producers like Eubacterium_hallii_group.
• Thrombocytopenia associated with Eubacterium limosum depletion; hepatotoxicity with Eubacterium_hallii_group and Burkholderia-Caballeronia-Paraburkholderia depletion.

Conclusions:

• Distinct gut microbiota signatures correlate with specific chemotherapy-related adverse events.
• These findings highlight the potential of the gut microbiome as a biomarker for toxicity prediction.
• Personalized cancer treatment strategies may be developed by leveraging microbiome data to mitigate chemotherapy side effects.